Literature DB >> 22052624

Systematic review of the epidemiology of systemic lupus erythematosus in the Asia-Pacific region: prevalence, incidence, clinical features, and mortality.

Rupert W Jakes1, Sang-Cheol Bae, Worawit Louthrenoo, Chi-Chiu Mok, Sandra V Navarra, Namhee Kwon.   

Abstract

OBJECTIVE: Systemic lupus erythematosus (SLE), a chronic multisystem autoimmune disease with a wide spectrum of manifestations, shows considerable variation across the globe, although there is little evidence to indicate its relative prevalence in Asia. This review describes its prevalence, severity, and outcome across countries in the Asia-Pacific region.
METHODS: We conducted a systematic literature search using 3 groups of terms (SLE, epidemiology, and Asia-Pacific countries) of EMBase and PubMed databases and non-English language resources, including Chinese Wanfang, Korean KMbase, Korean College of Rheumatology, Japana Centra Revuo Medicina, Taiwan National Digital Library of Theses and Dissertations, and Taiwanese, Thai, and Vietnamese journals.
RESULTS: The review showed considerable variation in SLE burden and survival rates across Asia-Pacific countries. Overall crude incidence rates (per 100,000 per year) ranged from 0.9-3.1, while crude prevalence rates ranged from 4.3-45.3 (per 100,000). Higher rates of renal involvement, one of the main systems involved at death, were observed for Asians (21-65% at diagnosis and 40-82% over time) than for whites. While infections and active SLE were leading causes of death, a substantial proportion (6-40%) of deaths was due to cardiovascular involvement. The correlation between the Human Development Index and 5-year survival was 0.83.
CONCLUSION: This review highlights the need to closely monitor Asian SLE patients in Asian countries for renal and cardiovascular involvement, especially those who may not receive proper treatment and are therefore at greater risk of severe disease. We hope this will encourage further research specific to this region and lead to improved clinical management.
Copyright © 2012 by the American College of Rheumatology.

Entities:  

Mesh:

Year:  2012        PMID: 22052624     DOI: 10.1002/acr.20683

Source DB:  PubMed          Journal:  Arthritis Care Res (Hoboken)        ISSN: 2151-464X            Impact factor:   4.794


  79 in total

1.  Commercial rodent diets differentially regulate autoimmune glomerulonephritis, epigenetics and microbiota in MRL/lpr mice.

Authors:  Michael R Edwards; Rujuan Dai; Bettina Heid; Thomas E Cecere; Deena Khan; Qinghui Mu; Catharine Cowan; Xin M Luo; S Ansar Ahmed
Journal:  Int Immunol       Date:  2017-06-01       Impact factor: 4.823

2.  Methyl-CpG-Binding Protein 2 (MECP2) Polymorphism in Iranian Patients with Systemic Lupus Erythematosus.

Authors:  Samira Alesaeidi; Jafar Karami; Mahdi Mahmoudi; Mahmoud Akbarian; Shiva Poursani; Azadeh Amirzadeh; Nazgol-Sadat Haddadi; Elahe Saffari; Ahmad Reza Jamshidi
Journal:  Inflammation       Date:  2015-12       Impact factor: 4.092

3.  Association of interleukin-1 receptor-associated kinase (IRAK1) gene polymorphisms (rs3027898, rs1059702) with systemic lupus erythematosus in a Chinese Han population.

Authors:  Yu Zhai; Ke Xu; Rui-Xue Leng; Han Cen; Wei Wang; Yan Zhu; Mo Zhou; Chen-Chen Feng; Dong-Qing Ye
Journal:  Inflamm Res       Date:  2013-02-23       Impact factor: 4.575

4.  Clinicopathological and outcome analysis of adult lupus nephritis patients in China.

Authors:  Yi Tang; XiaoYan Zhang; Ling Ji; XuHua Mi; Fei Liu; LiChuan Yang; Wei Qin
Journal:  Int Urol Nephrol       Date:  2015-01-07       Impact factor: 2.370

5.  Infection mitigation a necessity in lupus patients.

Authors:  Peiyun Liu; Hui Zhuan Tan; Huihua Li; Jason Chon Jun Choo; Cynthia Ciwei Lim
Journal:  Clin Rheumatol       Date:  2018-10-23       Impact factor: 2.980

Review 6.  Why targeted therapies are necessary for systemic lupus erythematosus.

Authors:  L Durcan; M Petri
Journal:  Lupus       Date:  2016-09       Impact factor: 2.911

7.  Population pharmacokinetic and pharmacodynamic analysis of BIIB023, an anti-TNF-like weak inducer of apoptosis (anti-TWEAK) monoclonal antibody.

Authors:  Gerald R Galluppi; Nicolas Wisniacki; Chris Stebbins
Journal:  Br J Clin Pharmacol       Date:  2016-04-08       Impact factor: 4.335

8.  Anti-C1q Antibody is Associated with Renal and Cutaneous Manifestations in Asian Indian Patients with Systemic Lupus Erythematosus.

Authors:  Jayakanthan Kabeerdoss; Nikhil Gupta; Sandhya Pulukool; Hindhumathi Mohan; Gowri Mahasampath; Debashish Danda
Journal:  J Clin Diagn Res       Date:  2017-03-01

9.  Prevalence and incidence of systemic lupus erythematosus in South Korea.

Authors:  Jee-Seon Shim; Yoon-Kyoung Sung; Young Bin Joo; Hye-Soon Lee; Sang-Cheol Bae
Journal:  Rheumatol Int       Date:  2013-12-10       Impact factor: 2.631

10.  Toward electronic health recording: evaluation of electronic patient reported outcome measures (e-PROMs) system for remote monitoring of early systemic lupus patients.

Authors:  Y El Miedany; M El Gaafary; Nadia El Aroussy; S Bahlas; M Hegazi; D Palmer; S Youssef
Journal:  Clin Rheumatol       Date:  2017-05-31       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.